Payment overview · 2025
General Payments
$2,207.47
97 reported records · 29 companies
Healthcare provider profile · identity verified
Mohammed Y Pathan, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · COLUMBUS, GA · NPI 1073575288
Verified facts
What the public records show
CMS Open Payments records show Mohammed Y Pathan, MD received $2,207.47 in general payments during 2025 across 97 reported records.
ABBVIE INC. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Fycompa, Gamunex-C, Nurtec Odt, Qulipta, Tysabri, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Fycompa by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gamunex-C by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Epidiolex by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $357.10 | 16.2% | 22 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $209.77 | 9.5% | 7 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $175.39 | 8.0% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $158.44 | 7.2% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $146.01 | 6.6% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $103.82 | 4.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $100.44 | 4.5% | 5 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$98.52 | 4.5% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $97.27 | 4.4% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $87.41 | 4.0% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $85.28 | 3.9% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $67.44 | 3.1% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $63.38 | 2.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.55 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.05 | 2.0% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $41.69 | 1.9% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $38.35 | 1.7% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $35.73 | 1.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $35.67 | 1.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.22 | 1.3% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $25.46 | 1.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.68 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.34 | 1.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.99 | 1.0% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $19.56 | 0.9% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $18.87 | 0.8% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $18.23 | 0.8% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $15.26 | 0.7% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $14.55 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,207.47 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $190.09 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $175.10 | 13 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $158.44 | 9 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $150.59 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $146.01 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $130.82 | 12 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $117.19 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $103.82 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $100.44 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $100.44 | 5 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $98.52 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $97.27 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $87.41 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $87.41 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $85.28 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $67.44 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $59.18 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $49.55 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $40.89 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $38.35 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $35.73 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 98 | exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 51 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 49 | exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 99 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
98 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
99 | 32 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
51 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 749 | 136 |
| Donepezil Hcl | Donepezil Hcl | 563 | 161 |
| Gabapentin | Gabapentin | 470 | 120 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 448 | 115 |
| Lamotrigine | Lamotrigine | 372 | 57 |
| Zonisamide | Zonisamide | 307 | 84 |
| Primidone | Primidone | 256 | 63 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 248 | 79 |
| Memantine Hcl | Memantine Hcl | 244 | 56 |
| Rizatriptan | Rizatriptan Benzoate | 233 | 74 |
| Sumatriptan Succinate | Sumatriptan Succinate | 230 | 73 |
| Clonazepam | Clonazepam | 203 | 32 |
| Topiramate | Topiramate | 195 | 52 |
| Baclofen | Baclofen | 177 | 25 |
| Pregabalin | Pregabalin | 164 | 42 |
| Emgality Pen | Galcanezumab-Gnlm | 157 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 40 |
| Lacosamide | Lacosamide | 148 | 22 |
| Aimovig Autoinjector | Erenumab-Aooe | 142 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 127 | 27 |
| Phenobarbital | Phenobarbital | 117 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 25 |
| Meclizine Hcl | Meclizine Hcl | 105 | 41 |
| Nortriptyline Hcl | Nortriptyline Hcl | 105 | 40 |
| Ubrelvy | Ubrogepant | 99 | 32 |
| Botox | Onabotulinumtoxina | 98 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 64 | 16 |
| Divalproex Sodium | Divalproex Sodium | 59 | 12 |
| Carbamazepine | Carbamazepine | 58 | 17 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 56 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 52 | 11 |
| Fycompa | Perampanel | 52 | suppressed |
| Lorazepam | Lorazepam | 52 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 51 | 19 |
| Qulipta | Atogepant | 49 | 13 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 19 |
| Prednisone | Prednisone | 44 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 44 | 13 |
| Trazodone Hcl | Trazodone Hcl | 41 | 13 |
| Vumerity | Diroximel Fumarate | 41 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Tysabri | Natalizumab | 37 | suppressed |
| Diazepam | Diazepam | 35 | 23 |
| Promethazine Hcl | Promethazine Hcl | 34 | 13 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Neupro | Rotigotine | 33 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 32 | suppressed |
| Droxidopa | Droxidopa | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 29 | suppressed |
| Lamotrigine Odt | Lamotrigine | 28 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Scopolamine | Scopolamine | 25 | 12 |
| Methylprednisolone | Methylprednisolone | 24 | 18 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 20 | suppressed |
| Acetazolamide Er | Acetazolamide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Clobazam | Clobazam | 19 | suppressed |
| Kesimpta Pen | Ofatumumab | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 18 | suppressed |
| Levetiracetam Er | Levetiracetam | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 16 | suppressed |
| Teriflunomide | Teriflunomide | 16 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 14 | suppressed |
| Fingolimod | Fingolimod Hcl | 14 | suppressed |
| Vimpat | Lacosamide | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Glatopa | Glatiramer Acetate | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,207.47 · 97 records | ABBVIE INC. | BOTOX, BRIUMVI, Briviact, CREXONT, FYCOMPA, Gamunex-C, General - DBS, INSPIRE, KESIMPTA, Leqembi, NEURACEQ, NUPLAZID, NURTEC ODT, PONVORY, QULIPTA, REXULTI, Rystiggo, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, XYWAV, ZAVZPRET, ZEPOSIA, Zilbrysq | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error